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Oxidative stressWe have used the human neuroblastoma cell line SH-SY5Y overexpressing Bcl-xL (SH-SY5Y/Bcl-xL) to clarify the
effects of this mitochondrial protein on the control of mitochondrial dynamics and the autophagic processes
which occur after the inhibition of leucine-rich repeat kinase 2 (LRRK2) with GSK2578215A. In wild type (SH-
SY5Y/Neo) cells, GSK2578215A (1nM) caused a disruption ofmitochondrialmorphology and an imbalance in intra-
cellular reactive oxygen species (ROS) as indicated by an increase in dichloroﬂuorescein ﬂuorescence and 4-
hydroxynonenal. However, SH-SY5Y/Bcl-xL cells under GSK2578215A treatment, unlike the wild type, preserved
a high mitochondrial membrane potential and did not exhibit apoptotical chromatins. In contrast to wild type
cells, in SH-SY5Y/Bcl-xL cells, GSK2578215A did not induce mitochondrial translocation of neither dynamin related
protein-1 nor the proapoptotic protein, Bax. In SH-SY5Y/Neo, but not SH-SY5Y/Bcl-xL cells, mitochondrial fragmen-
tation elicited byGSK2578215Aprecedes an autophagic response. Furthermore, the overexpression of Bcl-xL protein
restores the autophagic ﬂux pathway disrupted by this inhibitor. SH-SY5Y/Neo, but not SH-SY5Y/Bcl-xL cells,
responded to LRRK2 inhibition by an increase in the levels of acetylated tubulin, indicating that this was abrogated
byBcl-xL overexpression. This hyperacetylationof tubulin took place earlier than anyof the above-mentioned events
suggesting that it is involved in the autophagic ﬂux interruption. Pre-treatment with tempol prevented the
GSK2578215A-induced mitochondrial fragmentation, autophagy and the rise in acetylated tubulin in SH-SY5Y/
Neo cells. Thus, these data support the notion that ROS act as a second messenger connexion between LRRK2
inhibition and these deleterious responses, which are markedly alleviated by the Bcl-xL-mediated ROS generation
blockade.
© Elsevier B.V. All rights reserved.20151. Introduction
Mitochondrial dynamics, ﬁssion and fusion, are critical for cell preser-
vation and thus, impairments of these dynamics have important conse-
quences for the fate of the cell [1,2]. Mitochondrial ﬁssion is involved in
the physiopathology of numerous diseases that include neurodegenera-
tive disorders [3,4]. It is known that excessive ﬁssion can stimulate apo-
ptosis [5] and both processes have been related with neurodegenerative
processes [6]. Furthermore, when mitochondrial fragmentation is over-
done, a massive production of reactive oxygen species (ROS) takes place
in the mitochondria causing cell injury [3,4]. The proteins that regulate
these processes are either cytosolic (dynamin related protein-1 (Drp-1)
and Bax) or bound to the mitochondrial membrane (OPA, mitofusin-1,
Fis1 and Bcl-xL). Speciﬁcally, some anti-apoptotic Bcl-2 family members,ología Traslacional, Complejo
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lindo), joaquin.jordan@uclm.essuch as Bcl-w, have been proposed for the regulation of the development
of mitochondrial features [7]. Other members of this family, Bcl-xL and
Bax proteins, bind tightly to mitofusins and act as mitochondrial fusion
inhibitors [7,8]. Furthermore, some of these proteins have common
functions and roles in cell death pathways. For example, Bcl-xL protects
neuroblastoma cells against drug-induced neurodegenerative insults
[9]. Moreover, deletion of Bcl-xL results in a massive apoptotic cell
death [10,11]. There is ample evidence showing that Bcl-xL avoids
mitochondrial disruption features such as transmembrane potential
collapse, permeability transition pore formation, ROS generation, or
mitochondrial multiple conductance channel opening [9,12].
Macroautophagy (hereafter referred to as autophagy) is a catabolic
cellular pathway aimed to recycle cytoplasmic material and damaged
organelles [13,14]. The process of autophagy requires regulated pathways
for the formation of autophagosomes, double-membrane vesicles that en-
gulf material, and for the subsequent fusion with lysosomes forming
autolysosomes [15]. Not surprisingly, pathways involved inmitochondrial
dynamics and in autophagic processes are interconnected [16–18]. In this
sense, intermediate molecules of one pathway affect the other pathways.
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acetylation and this process has been shown to be implicated in both,
mitochondrial dynamics and autophagy [19]. Not only can the integrating
molecules be common for both routes. Critical regulatory molecules, like
the phylogenetically old Bcl-2 proteins can affect the two pathways at
the same time. This is the case of Bcl-xL, able to control both, autophagy
and apoptosis [20].
Leucine-rich repeat kinase 2 (LRRK2), is a ubiquitously expressed
enzyme, located in the cytoplasm as well as associated to the mitochon-
drialmembrane. It has two enzymatic domains, a GTPase (Ras of Complex
Proteins, ROC) and a kinase, connected by a C-terminal of ROC (COR).
Among its candidate substrates are, LRRK2 itself [21] and a broad number
of cytoskeleton-related proteins [22–25]. The exact function of this kinase
is still unknown. However, evidence supports that LRRK2 is related to the
pathogenesis of several diseases including Parkinson disease [26,27],
Crohn's disease [28] and cancer [29]. Mutations of LRRK2, as seen in
these diseases, confer the kinase an aberrant increased activity (toxic
gain-of-function) that results in cellular toxicity [29–31]. Moreover,
LRRK2 is indeed a putative stress response protein [32] and the transient
expression of this kinase has been shown to be toxic [33]. All these facts
have prompted pharmacologists' interest in LRKK2 as a therapeutic target
[34] and consequently, speciﬁc inhibitors have been developed [35].
2-arylmethyloxy-5-substitutent-N-arylbenzamide (GSK2578215A)
appears to be a potent LRRK2 inhibitor and exhibits an exceptionally
high selectivity for this kinase [36]. Despite the expectancy of LRRK2
inhibitors to obtain useful effects in Parkinson disease, we, and others,
have shown that GSK2578215A induces disruption of the cellular stress
responses includingmitochondrial dynamic impairment and activation
of autophagy [37]. In the presentwork,we have explored the role of Bcl-
xL as a regulator of autophagy and cell death in response to LRRK2 inhi-
bition elicited with GSK2578215A. We demonstrate that Bcl-xL abro-
gates the cytotoxic effects of LRRK2 inhibition in a neuroblastoma cell
line (SH-SY5Y/Bcl-xL) overexpressing Bcl-xL. We also explore the roles
of ROS in these protective actions.
2. Material and methods
2.1. Reagents and plasmids
DMEM-F12, penicillin–streptomycin, gentamicin and fetal bovine
serum (FBS) were obtained from Gibco-Invitrogen. GSK2578215A was
obtained fromTocris Bioscience; BCA protein assay fromPIERCE (Pierce,
Rockford, IL, USA). The pDsRed2-mito vector was provided by Clontech,
GFP-LC3 from Dr. JM Fuentes (Universidad de Extremadura, Spain),
mRFP-GFP-LC3 was provided by Dr. E Kneck (Laboratory of Cellular
Biology, Centro de Investigación Príncipe Felipe, Valencia, Spain). Drp1-
GFP was provided by T Wilson and Dr. S Strack (Dept. Pharmacology,
University of Iowa Carver College of Medicine), and GFP-Bax was a gift
from Dr. JHM Prehn (Department of Physiology and RCSI Neurosci-
ence Research Centre, Royal College of Surgeons, Ireland). Anti-4
hydroxynonenal antibody was obtained from Abcam (Cambridge,
UK); Alexa Fluor 488 fromMolecular Probes (Life Technologies, Carlsbad
CA, USA), anti-acetylated tubulin was from Sigma-Aldrich (St. Louis, MO,
USA) and anti-Bcl-xL was from Santa Cruz Biotechnology (Heidelberg,
Germany). Finally, tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-
N-oxyl) and L-buthionine sulfoximine (L-BSO) were purchased at
Calbiochem (La Jolla, CA, USA).
2.2. Cell culture and drug treatment procedures
SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cell lines were provided by Dr. JX
Comella (Fundacio Institut de Recerca de l'Hospital Universitari de la Vall
d'Hebron, Barcelona, Spain) [9]. Cell cultures were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM-F12) supplemented with 2 mM L-
glutamine, 20 U ml−1 penicillin–streptomycin, 5 mgml−1 gentamicin
and 15% (v/v) FBS. Cells were grown in a humidiﬁed cell incubator at37 °C under a 5% CO2 atmosphere. GSK2578215A was added to the
culture medium at a ﬁnal concentration of 1 nM. Pre-treatments
with tempol (0.2 μM) or BSO (100 μM) were added 30 min before
treatment. The absence of cell death induction by treatment in
control cells was systematically veriﬁed.2.3. Cell viability
Cell viability was analyzed by phase-contrast microscopy. Healthy
cells were identiﬁed as having smooth, phase-bright cell bodies and
intact neurites. Cells exhibiting a rough appearance with irregular shaped
cell bodies, blebs and vacuoles, followed by cell shrinkage, and loss of
phase-brightness, were considered to be damaged. We performed the
experiments using a “blind” counter. A total of 200–400 cells were exam-
ined in three to ﬁve randomized subﬁelds of the coverslips. Results are
expressed as the percentage of cell survival as compared to untreated
cells. Each condition was represented by three coverslips. All the experi-
ments were performed in quadruplicate.2.4. Chromatin state
SH-SY5Y cells were spotted on poly D-lysine-coated glass slides.
After treatment, the glass slides were rinsed three times with PBS and
then incubated with 0.5 μg/ml of Hoechst 33342 (Molecular Probes) for
5min at room temperature. After two rinseswith PBS, chromatin staining
was analyzed using a ﬂuorescent microscope. Uniformly stained nuclei
were scored as healthy, viable cells, condensed or fragmented nuclei
were counted as apoptotic.2.5. Transfections
Twenty-four hours before transfection, cells were plated at a density
of 5.3× 104 cells/cm2 on IDIBI-coated-dishes. Transfectionwas achieved
using Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer's protocol. Cells were transfected with the follow-
ing plasmids (structure to be visualized): pDsRed2 (mitochondrialmor-
phology), GFP-Drp1 and GFP-Bax (mitochondrial translocation), GFP-
LC3 (autophagic structures), and mRFP-GFP-LC3 (autophagosomes
and autolysosomes). After 4 h of incubation, the transfection mixture
was removed and replaced with fresh complete medium. The experi-
ments were performed 24 h after transfection to allow protein expres-
sion. To knock down LRRK2, cells were cotransfected with
Lipofectamine 2000 (Invitrogen) using LRRK2 Stealth RNAi duplexes
(Invitrogen) and the plasmid encoding pDsRed2 as described by the
manufacturer.2.6. Mitochondrial morphology
Cells were transfected with pDsRed2-mito, which leads to the
expression of ﬂuorescent DsRed2 in mitochondria, thereby labeling
the organelles. The transfected cells were then subjected to experimen-
tal treatments to evaluate mitochondrial morphology. For quantiﬁcation,
the percentage of cells with abnormal mitochondrial morphologies was
determined and used as a unit of measure of the proportion of cells
with fragmented mitochondria. Most of the cells had either fragmented
or ﬁlamentous mitochondria, whereas a small percentage of the cells
contained both fragmented and ﬁlamentous mitochondria. In the latter
case, themitochondrial morphologywas classiﬁed according to thema-
jority (N70%) of the mitochondria. The monitoring of mitochondrial
morphology was performed by two “blind” independent examiners
on three different cultures. Micrographs were processed with Huygens
Deconvolution Software (Scientiﬁc Volume Imaging) and Adobe
Photoshop.
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Total RNA from cell culture dishes was extracted using an RNeasy
Mini Kit (QIAGEN, Venlo, The Netherlands), and cDNA was synthetized
using TaqMan Reverse Transcription Reagents (APPLIED BIOSYSTEMS,
Life Technologies) in a thermal cycler UNO Cycler (VWR, Radnor, PA,
USA). First strand cDNA was used as template for real-time PCR using
a 7500 Fast Real-Time PCR System (APPLIED BIOSYSTEMS) with Fast
SYBR Green Master Mix (APPLIED BIOSYSTEM) and primers at 0.25 μM.
The threshold cycle (CT) values for each target mRNA were normalized
to 16S mRNA, and the relative expression of each target genewas calcu-
lated with the formula 2−ΔΔCt.
DRP1 Reverse primer 5′TGCGACCATCTGGATCTACCTCTCTT3′; FIS1
Forward primer 5′TCTGTGGAGGACCTGCTGAAGTTTGA3′;FIS1 Reverse
primer 5′CAGGTAGAAGACGTAATCCCGCTGTT3′;MNF1, Forwardprimer
5′TGCTGGCTAAGAAGGCGATTACTGCA3′; MNF1 Reverse primer 5′TCTC
TCCGAGATAGCACCTCACCAAT3′; OPA1 Forward primer 5′TTTGCGGA
GGACAGCTTGAGGGTTAT3′; OPA1 Reverse primer 5′CTCTTTTTCCAGTC
TGGACCCACCAT3′; DRP1 Forward primer 5′CACTTGTGGATTTGCCAG
GAATGACC3′; 16S Forward primer 5′CGCATAAGCCTGCGTCAGATAAAA
3′; 16S Reverse primer 5′TGTGTTGGGTTGACAGTGAGGGTA3′.
2.8. Evaluation of mitochondrial translocation of GFP-Drp1 and GFP-Bax
The procedurewas based on a transient transfection of cells with the
corresponding ﬂuorescence construct and confocal microscopy. In brief,
cells were plated for 24 h before transfection, then incubated for 24 h to
allow for sufﬁcient expression and ﬁnally treated with GSK2578215A.
Cells were observed under confocal microscopy. Mitochondrial translo-
cation of the construct implied the shift from a cytoplasmic diffuse
green ﬂuorescence to a brighter and spotted one localized in the mito-
chondria. The total number of transfected cells and those displaying
the spotted patternwas quantiﬁed under confocal microscopy. The per-
centage of spotted over transfected cells was calculated, and a mean ±
SD of several independent experiments was obtained.
2.9. Analysis of mitochondrial membrane potential
To assess changes in mitochondrial membrane potential, SH-SY5Y/
Neo and SH-SY5Y/Bcl-xL cells, treated or untreated with GSK2578215A,
were incubated for 10 min with 10 μg/ml of JC-1 ﬂuorescent dye for
20 min (Molecular Probes) and washed with Krebs medium. For quanti-
ﬁcation of mitochondrial membrane potential disruption, JC-1 stained
cells were observed under the confocal microscope, and the green/red
ﬂuorescent ratio (JC-1) was quantiﬁed by measuring optical density
with ImageJ software (National Institute of Mental Health, Bethesda,
MD, USA).
2.10. Determination of cellular ROS
Cellular ROS levels were measured using 2′7′-dichlorodihydro-
ﬂuorescein diacetate (CM-H2DCFDA, Molecular Probes), which is
converted to a non-ﬂuorescent derivative (H2DCF) by intracellular
esterases. H2DCF molecule is oxidized by ROS producing dichloro-
ﬂuorescein (DCF), which is a ﬂuorescent compound. SH-SY5Y cells
were incubated with 10 μM of H2DCFDA for 15 min at 37 °C. Cells were
examined under a confocal microscope. Intracellular ROS production
was assessed by quantifying theDCF greenﬂuorescent levels using ImageJ
software.
2.11. Quantiﬁcation of mitochondrial ROS
To monitor mitochondrial ROS production, cells were treated or not
with GSK2578215A and after incubation at the indicated time, cells
were incubatedwithMitoSOX(2.5 μM) (Molecular Probes, Life Technol-
ogies) for 10 min at 37 °C and then washed with Krebs medium. Forquantiﬁcation, cells were observed under the confocal microscope and
the red ﬂuorescence levels were measured using ImageJ software
(National Institute of Mental Health, Bethesda).
2.12. Autophagic cells
Cells were transfected with GFP-LC3, which leads to the expression
of ﬂuorescent LC3, the universal marker protein of autophagic struc-
tures in mammalian and yeast cultured cells. The transfected cells are
then subjected to experimental treatments to evaluate the percentage
of autophagic cells. Non-treated cells showed diffuse cytosolic LC3 dis-
tribution whereas the appearance of LC3-positive puncta is indicative
of autophagy induction. For quantiﬁcation, every cell with more than
six autophagosomes per cell was considered as an autophagic cell. To
study the effect of GSK2578215A on autophagosome maturation, SY5Y/
Neo and SH-SY5Y/Bcl-xL cells were transfected with an mRFP-GFP-LC3
tandem reporter that was found to be useful to trace autophagosome
maturation. Within lysosomes, GFP-LC3 ﬂuorescence was quenched
because of the sensitivity of GFP to acidic environments, whereas
mRFP-LC3 ﬂuorescence was more stable upon acidiﬁcation. Thus,
autophagosomes with a physiological pH show both red and green
ﬂuorescence (yellow dots), whereas the latter was lost in
autolysosomes with an acidic pH (red dots). After overlapping images
in both channels, the number of LC3 dots in each cell was analyzed:
RFP+/GFP+ (yellow) dots as autophagosomes and RFP+/GFP− (red)
dots as autolysosomes. Therefore, the percentage of red dots (RFP+/
GFP−) in each cell is a measure of the number of autolysosomes. For
each condition, at least, 30 transfected cells were counted. Cells were
viewed under a laser scanning microscope (LSM 170; Carl Zeiss).
2.13. Western blotting
SH-SY5Y cell cultures were washed twicewith ice cold PBS and then
collected by mechanical scraping with 1 ml of PBS per tissue culture
dish. The suspension was centrifuged at 12,000–14,000 rpm for 5 min.
The supernatant was discarded, and the pellet was brought up in
100 μl of a sample buffer. The protein from each condition was quanti-
ﬁed spectrophotometrically (Micro BCA Protein Reagent Kit, Pierce,
Rockford, IL, USA), and an equal amount of protein (30 μg) was loaded
onto 10% SDS-PAGE gels. After electrophoresis, proteins were trans-
ferred to polyvinylidene diﬂuoride membranes (Immobilon; Millipore
Corporation, Billerica, MA, USA). Nonspeciﬁc protein binding was
blocked with Blotto (4% w/v nonfat dried milk, 4% bovine serum albu-
min (Sigma-Aldrich), and 0.1% Tween 20 (Sigma-Aldrich) in PBS for
1 h. The membranes were incubated with a 1:1000 of dilution of anti-
Bcl-xL (Santa Cruz Biotechnology), anti-acetylated tubulin (Sigma-
Aldrich) and α-Tubulin (Santa Cruz Biotechnology). After washing
with Blotto, the membranes were incubated with peroxidase-labeled
anti-rabbit or anti-mouse secondary antibodies (Promega, Promega:
Madison,WI, USA) in Blotto. The signal was detected using an enhanced
chemiluminescence detection kit (GE Healthcare, Little Chalfont, Buck-
inghamshire, UK). Band intensities were estimated densitometrically
on a GS-800 calibrated densitometer (Bio-Rad Quantity One, Hercules,
CA, USA).
2.14. Immunocytoﬂuorescence staining
For assessment of 4-hydroxynonenal immunoﬂuorescence, SH-SY5Y
cells were plated on poly-L-lysine-coated glass slides. Cells were ﬁxed
with 4% paraformaldehyde in PBS 10 min at 37 °C and washed twice
with PBS. After permeabilization, cells were incubated overnight with
anti-4 hydroxynonenal (4HNEJ-2, Abcam, Cambridge, UK), at 4 °C. Then
cells were incubated with ﬂuorescent-conjugated secondary antibodies
Alexa Fluor 488 (Molecular Probes) for 1 h at RT. 4-HNE expression was
quantiﬁed by measuring optical density with ImageJ software (National
Institute of Mental Health, Bethesda, Maryland). After quantiﬁcation, the
23S. Saez-Atienzar et al. / Biochimica et Biophysica Acta 1862 (2016) 20–31staining density was calculated by dividing the pixel count by the cell
number in order to obtain the number of pixels per cell.
3. Statistical analysis
Data shown are means ± SEM. Statistical signiﬁcance was deter-
mined by a two-tailed Student's test for impaired samples. The statisti-
cal signiﬁcance was set at p b 0.05.
4. Results
4.1. Bcl-xL protects SH-SY5Y cells against toxicity after GSK2578215A
treatment
We used the ﬂuorescence dye Hoechst 33342 to analyze nuclear
integrity. Afterwards, we calculated the percent of cells with apoptotical
features in their chromatins, including nuclei condensation or fragmen-
tation. After 12 h of treatment with GSK2578215A (1 nM), we detected
an increase in the percentage of SH-SY5Y/Neo cells with apoptotical
chromatin signs (Fig. 1A, left upper panel). Quantiﬁcation of the number
of cells with deathlike morphology was approximately 3-fold higher
than vehicle-treated cells (p b 0.01; Fig. 1A, right panel). In contrast,
only a small number of SH-SY5Y/Bcl-xL cells, challenged with the same
dose of GSK2578215A exhibited apoptotic marks (Fig. 1A, left lower
panel). Cell count assessment showed that the increase in deathlike SH-
SY5Y/Bcl-xL cells was signiﬁcantly lower than wild type cells (~25%
decrease, p b 0.05, Fig. 1A, right panel).
Mitochondrial membrane collapse (ΔΨm) is a marker of cell
death [38]. We have used the ratiometric ﬂuorescent dye, JC1, to
monitor ΔΨm. Regions of high mitochondrial membrane polariza-
tion appear in red ﬂuorescence, while depolarized regions are recog-
nized by a green ﬂuorescence (Fig. 1B). Green areas in Fig. 1B show
that depolarized mitochondria have a disrupted morphology, in con-
trast to the red-colored mitochondria, which are long and ﬁlamen-
tous. Fig. 1B also shows that SH-SY5Y/Bcl-xL cells treated with
GSK2578215A for 12 h display more red regions than wild type
cells do. Indeed, 3 h after GSK2578215A addition, the red-to-green
ﬂuorescence ratio was signiﬁcantly altered in SH-SY5Y/Neo but not
in SH-SY5Y/Bcl-xL cells.
In order to analyze whether GSK2578215A treatment induced
changes in the Bcl-xL protein levels in both SH-SY5Y/Neo and SH-
SY5Y/Bcl-xL cells, we monitored the Bcl-xL levels by using western
blot. As shown in Fig. 1C, the levels of Bcl-xL in total cellular extracts
were signiﬁcantly higher in SH-SY5Y/Bcl-xL cells than in the SH-SY5Y/
Neo. However, GSK2578215A treatment had no effect on the Bcl-xL
protein expression neither in SH-SY5Y/Neo nor in SH-SY5Y/Bcl-xL
cells.
4.2. Bcl-xL protects SH-SY5Y cells against GSK2578215A-inducedmitochon-
drial ﬁssion
Mitochondrialmorphologywas examined in cell cultures transiently
expressing mitochondrial protein DsRed2. Fig. 2A (left panels) shows
that both, SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cells, treated with DMSO
(vehicle), contained longmitochondria, forming a net with an homoge-
neous distribution. 12 h after GSK2578215A addition, the number ofmi-
tochondria with ﬁlamentous appearance decreased in SH-SY5Y/Neo
cells, and the net-like interconnection of mitochondria was disrupted
(Fig. 2A left upper panels). In contrast, under the same conditions,
GSK2578215A failed to alter mitochondrial morphological features in
SH-SY5Y/Bcl-xL cells (Fig. 2A left lower panels). Quantiﬁcation of
fragmentedmitochondria (Fig. 2A right panel) showed that Bcl-xL over-
expression completely abolished the deleterious GSK2578215A effects.
Next, we transiently overexpressed GFP-Drp-1 or GFP–Bax proteins in
both SH-SY5Y cell types to determine whether Bcl-xL affects the translo-
cation of these proteins induced by GSK2578215A. The analysis of GFPdistribution shows that untreated cultures displayed an homoge-
neous cytosolic distribution of both GFP-Drp-1 and GFP-Bax (Fig. 2B
and C). Wild type SH-SY5Y, but not SH-SY5Y/Bcl-xL cells, challenged for
12 h with GSK2578215A (1 nM) changed both GFP-Drp-1 and GFP-Bax
distribution to a punctuate pattern (Fig. 2B and C, left panels).
Cotransfection of these plasmids and pDsRed2-mito, showed
colocalization between GFP-Drp-1 and GFP-Bax and mitochondria, re-
spectively (Fig. 2B and C, insets). This indicates amitochondrial transloca-
tion of these proteins. Histograms depict the quantiﬁcation of punctuate
cells (Fig. 2B and C, right panels). Note that both GFP-chimerical proteins
remained within the cytosol in cell cultures overexpressing Bcl-xL.
To determine if Bcl-xL affects mitochondrial dynamic pathways,
mRNA levels of Drp1, Fis1, OPA and MFN1 were analyzed by RT-PCR
in cells challenged with GSK2578215A or vehicle (DMSO). Histogram
in Fig. 2D shows that GSK2578215A treatment increased the mRNA
levels of all these mitochondrial dynamic mediators in SH-SY5Y/Neo cell
cultures. In contrast, overexpression of Bcl-xL prevented the increase of
ﬁssion-related mRNAs (Drp1 and FIS1) but not fusion-related ones
(OPA1 and MFN1).
Finally, to verify if the above-described GSK2578215A-induced effects
are due to LRRK2 inhibition, SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cells were
co-transfected with siRNA to knock down LRRK2 expression. After 48 h,
mitochondrial morphology was analyzed and we observed a similar per-
centage of cells with fragmentedmitochondria in both cell lines (Fig. 2E).
These data demonstrate that the effect of GSK2578215A was a LRRK2-
dependent phenomenon and not an off-target effect of the inhibitor.
4.3. Bcl-xL modulates GSK2578215A-induced autophagy
Our next goal was to determine whether Bcl-xL overexpression
affects GSK2578215A-induced autophagy. To this end, we transiently
overexpressed GFP-LC3 plasmid in our cells. The left panel of Fig. 3A
depicts the confocal images of cells under different situations. Note that
the appearance of autophagic cells is visualized solely in GSK2578215A-
treated wild type cells. The histogram on the right panel of Fig. 3A
illustrates the quantiﬁcation of autophagic cells. The increase in the per-
centage of autophagic cells in SH-SY5Y/Neo cultures challenged with
GSK2578215A was signiﬁcantly higher (approx. 4-fold) than that in
SH-SY5Y/Bcl-xL cultures (approx. 30%).
Wehave used amRFP-GFP-LC3 tandem reporter to analyze the effect
of Bcl-xL overexpression on autophagic ﬂux [39,40]. Fig. 3B shows that
GSK2578215A increased the number of autophagosomes in wild type,
but not in SH-SY5Y/Bcl-xL, cell cultures as seen by the yellow-dotted
pattern in the confocal images (left panels) and yellow-dot counting
histograms (right panel). Autolysosome assessment, on the other hand,
showed that the number of autolysosomes was augmented in SH-SY5Y/
Bcl-xL, but not SH-SY5Y/Neo cells, when challenged with GSK2578215A,
as shown by the red dot display of the confocal pictures (Fig. 3B, left
panels) and the quantiﬁcation study (Fig. 3B, right panel). These data
indicate that Bcl-xL overexpression restores the autophagy ﬂux pathway
disrupted by GSK2578215A treatment.
4.4. Bcl-xL abrogates GSK2578215A induction of acetylated tubulin levels
Tubulin, themajor component of microtubule cytoskeleton, is a sub-
strate for LRRK2 [41] thus alterations in the acetylated levels of tubulin
are associated to those of LRRK2 activity [42]. Immunocytoﬂuorescence
staining and immunoblotting were used to determine the effects of
Bcl-xL overexpression in this process. Confocal microcopy detected
an increased intensity of acetylated tubulin immunoﬂuorescence
in SH-SY5Y/Neo, but not in SH-SY5Y/Bcl-xL, cell cultures challenged for
12 h with GSK2578215A (Fig. 4A). Immunoblotting of total extracts
obtained from SH-SY5Y cells, treated or untreated with GSK2578215A
for 3 and 12h, corroborated thisﬁnding (Fig. 4B). A representative immu-
noblot shown in the right panel of this ﬁgure illustrates how the increase
in acetylated tubulin levels was already present in SH-SY5Y/Neo cells
Fig. 1. Bcl-xL protects SH-SY5Y cells against GSK2578215A-induced cytotoxicity. A. Confocal images of SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cell chromatins stained with Hoechst 33342 (left
panels). Histogram depicting the percentage of SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cells with deathlike morphology counted after 24 h of incubation with GSK2578215A (right panel). Both ap-
proaches indicate amore favorable survival outcomeof SH-SY5Y/Bcl-xL cells comparedwith thewild type control. B. Confocal images of SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cells stainedwith JC-1
ﬂuorescent dye to assessmitochondrialmembrane potential disruption (left panels). Histogram showing red/green JC-1 ﬂuorescent ratio indicates that SH-SY5Y/Bcl-xL cellsmaintain the levels
of transmembrane mitochondrial potential after 3 and 12 h of GSK2578215A treatment (right panel). In every case vehicle was DMSO and GSK2578215A incubated at 1 nM for 24 h (A and
B) and 12 h (C and D). C. Representative western blots (left panel) and densitometrical analysis (right panel) showing Bcl-xL protein levels in total lysates of SH-SY5Y/Neo and SH-SY5Y/Bcl-
xL cells treated or untreated for 12h with GSK2578215A. GADPH was used as a loading control. Scale bars 20 μm (A) and 10 μm (B). Histogram data are the mean ± SEM of at least three in-
dependent experiments, each performed in triplicate. Statistical signiﬁcance was determined by a two-tailed Student's test: N.S. non-signiﬁcant, *p b 0.05, **p b 0.01.
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remain similar to those found in untreated cultures.
4.5. Bcl-xL plays an anti-oxidant role
Mitochondrial-derived ROS have been proposed to function as
key second messengers when mitochondria have undergone a dis-
ruption process [4,43]. With this notion in mind, we monitored
ROS levels by means of dichloroﬂuorescein (DCF). The graph
depicted in Fig. 5A shows that SH-SY5Y/Neo, but not in SH-SY5Y/
Bcl-xL cells, gradually increased DCF ﬂuorescence levels (Fig. 5A), indi-
cating an excess in mitochondrial ROS production, which was maximal
after 12 h of exposure to GSK2578215A. Next, we measured 4-hydroxynonenal, which is regarded as a hallmark of oxidative stress
[44]. SH-SY5Y/Neo cells challenged with 1 nM GSK2578215A for 24 h
presented, unlike SH-SY5Y/Bcl-xL cells, signiﬁcantly higher levels of
4-hydroxynonenal (Fig. 5B). This ﬁnding is consistent with an anti-
oxidant role of Bcl-xL. Next, we studied whether the observed ROS in-
crease was produced by mitochondria. To this end, we used the
ﬂuorogenic dyeMitoSOX. As shown in Fig. 5C,MitoSOX ﬂuorescent levels
raise after 3 h upon GSK2578215A treatment in SH-SY5Y/Neo, but not in
SH-SY5Y/Bcl-xL cells.
In order to study the role of glutathione (GSH), a plausible antioxidant
mechanism mediated by Bcl-xL [9], we induced a depletion of its cellular
stores by incubation with buthionine sulfoximine (BSO) (100 μΜ) and
monitored the autophagy response. Interestingly, the addition of
Fig. 2.Bcl-xL abrogates GSK2578215A-inducedmitochondrial dynamic alterations as assessed bymitochondrialmorphology and translocation of BaxDrp-1. Representative confocal images (A–
C, left panels) of cells transfected after 24 hwith pDsRed2-mito vector (A), GFP-Drp-1 (B) andGFP-Bax plasmids (C). Histograms (A–C, left panels) representing the percentage of SH-SY5Y/Neo
and SH-SY5Y/Bcl-xL cells with fragmented mitochondria (A), punctate GFP-Drp-1 distribution (B) and punctate GFP-Bax distribution (C). Insets in B and D panels show colocalization of GFP-
Drp-1 or GFP-Bax andmitochondria (pDsRed2-mito vector), respectively. The three approaches indicate that Bcl-xL preventsmitochondrialmorphological alterations. In every case vehiclewas
DMSOandGSK2578215A incubated at 1nM for 12 h. Scale bars 10 μm. Panel DdepictsmRNA levels ofDrp1, Fis1,MFN1, andOPA as analyzedbyRT-PCR. E. Histogram representing the effects of
LRRK2 knockdown in SH-SY5Y/Neo and SH-SY5Y/Bcl-xL onmitochondriamorphology. Data shownare themean±SEMof at least three independent experiments, each performed in triplicate.
Statistical signiﬁcance was determined by a two-tailed Student's test: N.S. non-signiﬁcant, *p b 0.05, **p b 0.01, ***p b 0.001.
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Fig. 3.Bcl-xL blocks GSK2578215A-induced autophagy in SH-SY5Y cells. Confocal images (A–B, left panels) of cells transfectedwith the followingplasmids: GFP, to analyze autophagic cells
(A) andmRFP-GFP-LC3, to assay the formation of autophagosomes and autolysosomes (B). Cells were treated 24 h after transfectionwith vehicle (DMSO) or 1 nMGSK2578215A for 12 h.
A. Vehicle-treated cells showed diffuse cytosolic mRFP-GFP-LC3 distribution, while those treated with GSK2578215A presented a dot-like distribution (left panels). Histogram illustrates
the percentage of autophagic cells (right panel). B. Micropictures showing the presence of autophagosomes (yellow dots) and autolysosomes (red dots) (left panels). Histogram depicts
the number of autophagosomes and autolysosomes per cell (right panel). Both, the level of autophagic cell and autophagosome formation were lower in the SH-SY5Y/Bcl-xL cells. Scale
bars, 10 μm. Data shown are themeans± SEM of at least three independent experiments, each performed in triplicated. Statistical signiﬁcance was determined by a two-tailed Student's
test: N.S. non-signiﬁcant, *p b 0.05, **p b 0.01, ***p b 0.001.
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the percent of autophagic cells in basal conditions (Fig. 5D). Moreover,
BSO-pre-treatment reverted the abrogation effect induced by Bcl-xL over-
expression on GSK2578215A-induced autophagic response in SH-SY5Y
cells (Fig. 5D). Because we suspected that Bcl-xL might have an anti-
oxidant function within the mitochondria [45], we wished to ascertain
the effects induced by the superoxide dismutase mimetic, tempol.
We pre-treated cell cultures with tempol (0.2 μM, 30 min) before
GSK2578215A addition. Under these conditions, tempol decreased the
percentage of wild type SH-SY5Y cells exhibiting fragmented mitochon-
dria, as assessed by the percentage of ﬂuorescent DsRed2-labeled organ-
elles (Fig. 5E). This anti-oxidant treatment also prevented the increase in
the percentage of ﬂuorescent LC3-marked cells, the universal hallmark of
autophagy (Fig. 5F). Furthermore, tempol abrogated the rise in acetylated
tubulin induced by the GSK2578215A treatment (Fig. 5G).
5. Discussion
Hereinwe have tested the role of Bcl-xL protein on the effects induced
on mitochondrial dynamics upon LRRK2 inhibition attained with the
highly selective inhibitor GSK2578215A in a dopaminergic SH-SY5Y cell
line. Consistent with previous studies performed by others and ourselves
[37,46], GSK2578215A induced cytotoxicity which was associated to al-
terations in mitochondrial morphology and activation of mitophagy. Inthe present work, we attempted to shed light on the effects of Bcl-xL pro-
tein on these stressful processes. To this end, we used a SH-SY5Y stable
cell line overexpressing this mitochondrial protein (SH-SY5Y/Bcl-xL)
and compared it with a wild type cell line (SH-SY5Y/Neo). We have
found that overexpression of Bcl-xL preventsmitochondrial Drp-1 trans-
location and as a result, GSK2578215A-induced mitochondrial ﬁssion
is inhibited while autophagosome–lysosome fusion is restored. We
also report that Bcl-xL abrogates GSK2578215A-induced tubulin
hyperacetylation. Finally, our data suggest that Bcl-xL acts as a
mitochondrion-derived ROS scavenger.
The present data provide further evidence supporting the notion
that Bcl-2 family members are key regulatory elements of mitochondri-
al homeostasis [7,47,48]. Our study speciﬁcally focuses on Bcl-xL. This
protein inhibits the activation of the molecular pathways involved in
the alteration of the mitochondrial membrane potential [45]. In our
set-up, Bcl-xL overexpression conferred resistance to GSK2578215A-
induced mitochondrial ﬁssion in SH-SY5Y cells. As a consequence of
this, Bcl-xL maintained transmembrane mitochondrial potential at
basal levels (Fig. 1). Hence, mitochondria overexpressing Bcl-xL remain
functional even in the presence of GSK2578215A. Cells overexpressing
Bcl-xL kept Drp-1 protein within the cytosol. This prevented its activa-
tion and subsequent mitochondrial translocation. According to this, in
hippocampal neurons, Bcl-xL regulates Drp-1 effect on mitochondrial
function [49]. This effect is probably related with the anti-cell death
Fig. 4. Bcl-xL abrogates GSK2578215A-induced acetylation of tubulin. A. Confocal images of acetylated tubulin immunoﬂuorostaining (green) in SH-SY5Y/Neo and SH-SY5Y/Bcl-xL cells
treated with vehicle (DMSO) or 1 nM GSK2578215A for 24 h. Hoechst co-staining (blue) was used to stain cellular nuclei (scale bars, 20 μm) (left panels). Histogram representing the
acetylated tubulin ﬂuorescence levels from confocal images normalized to ﬂuorescence of vehicle-treated cells (right panel). B. Representative western blots (left panel) and histogram
showing the optical density ratio of acetylated tubulin/total tubulin in total lysates (30 μg) of cells treated with vehicle or 1 nM GSK2578215A for 3 or 12 h (right panel). Data shown
are the means ± SEM. Statistical signiﬁcance was determined by a two-tailed Student's test: N.S. non-signiﬁcant, *p b 0.05, **p b 0.01.
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observations made in our laboratory and elsewhere, have shown that
if Drp-1 is knocked down or inhibited, cells become more resistant to
cytotoxic stress [50–53].
To gain further insight on the biological consequences of
GSK2578215A treatment, we extended our study to the Bcl-2 family
member, Bax. GFP-Bax localization has been used in other cytotoxic
models tomonitor its translocation after stress stimuli [12,54]. In our ex-
periments, we detected Bax translocation in SH-SY5Y/Neo cell cultures
treated with GSK2578215A (Fig. 2). It is remarkable that this phenome-
non took place after Drp-1 translocation or mitochondrial ﬁssion oc-
curred. The timing sequence of these events is consistent with the
notion that Baxparticipates in cell death rather than in themitochondrial
ﬁssion pathway. Interestingly, and consistent with an anti-apoptotical
role of Bcl-xL, SH-SY5Y/Bcl-xL cells exhibit a lowermitochondrial expres-
sion of Bax. It must be pointed out that Bcl-xL protects SH-SY5Y cells
against GSK2578215A by an inhibition of mitochondrial Bax insertion
and loss of mitochondrial outer membrane permeability. Because mito-
chondrial Drp1 stimulates Bax oligomerization [55], it is plausible that
themechanism by which Bcl-xL abrogates Bax translocation is mediated
by the ability of the former protein to, in turn, block the translocation of
Drp-1.
In line with previous studies [37,46], SH-SY5Y/Neo type cells
respond to GSK2578215A treatment by inducing autophagy. Moreover,
GSK2578215A increased the percentage of autophagic cells, even after
the disruption of the autophagic ﬂux. Interestingly, SH-SY5Y/Bcl-xL cells
display a higher number of autolysosomes instead of autophagosomes
(Fig. 3). This indicates that Bcl-xL restores the autophagic process within
the cells.Our results are consistent with the action of Bcl-xL mediated by the
well-established ROS scavenging properties of this protein [45]. In fact,
cell cultures overexpressing Bcl-xL present lower levels of ROS produc-
tion (Fig. 5). Furthermore, when we depleted GSH levels by using BSO,
Bcl-xL abrogative capacity disappears and the depletion of this antioxi-
dant in basal conditions results in an induction of autophagia. Similar
results have been obtained by others in different cell types [56]. On
the other hand, these cells reveal a higher ROS scavenging power, able
to prevent the elevation of intracellular ROS production when deﬁed
with GSK2578215A. This is evidenced by the analysis of the oxidative
stress hallmarks, 4-HNE adducts, which have been shown to play a cen-
tral role in cytotoxicity and neurodegenerative processes [57] [58]. The
nature of the ROS implicated in our set-up remains unknown. However,
on the basis that superoxide anions are the primary regulators of cell-
death and autophagy [59], we studied the effects of a treatment with
the superoxide dismutase mimetic, tempol. Wild type cells under
this treatment proved to be more resistant to GSK2578215A-
induced mitochondrial features of disruption and autophagy.
We evidenced that LRRK2 inhibition leads to an increase in the levels
of tubulin acetylation as early as 3 h after GSK2578215A treatment and
these levels remained elevated even after 12 h. This was associatedwith
changes in the intracellular tubulin which would compromise a dynamic
process of assembly and disassembly of the microtubules [60]. Indeed, a
previous study demonstrated that pharmacological inhibition of LRRK2
increases the binding between LRRK2 and tubulin both in non-neural
and in neural cells, suggesting that LRRK2 and microtubules mutually in-
teract [61]. Furthermore, our data revealed that mitochondrial ﬁssion
takes place downstream of this event. Recent studies in PC12 cells show
that Bcl-2 is able to normalize the level of acetylated tubulin, even in
Fig. 5. Bcl-xL exhibits antioxidant properties. A. Levels of intracellular ROS assessed by DCF ﬂuorescence at different times points. B. Amount of intracellular ROS analyzed at 24 h bymeans
of 4-HNE inmunocytoﬂuorescence quantitation of confocal images, both in cells challengedwith vehicle (DMSO) or GSK2578215A, 1 nM. C. Histogram displays the levels ofmitochondrial
ROSmeasured byMitoSOX ﬂuorescent dye. D. Histogram illustrates the percentage of autophagic cells after GSK2578215A treatment in the presence or absence of BSO (100 μM). E and F.
Histograms representing percentage of SH-SY5Y/Neo cells with fragmented mitochondria (E) and percentage of autophagic cells (F). Cells were transfected with pDsRed2-mito (E) and
GFP-LC3 (F) plasmids. In both instances, cells were treated with tempol 30 min before GSK257815A addition. G. Representative immunoblots of acetylated and total tubulin levels in
SH-SY5Y/Neo cells treated or untreated with tempol (0.2 μM, 30 min) prior to GSK257815A (left panel). Histogram showing the optical density ratio of acetylated tubulin/total tubulin
bands (right panel). Histograms represent the means± SEM. Statistical signiﬁcance was determined by a two-tailed Student's test: N.S. non-signiﬁcant, *p b 0.05, **p b 0.01, ***p b 0.001.
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is possible that the Bcl-xL overexpression of our cells prevents tubulin
acetylation. Studies in hippocampal neurons reveal that acetylation of tu-
bulin is relatedwithmitochondrial transport. In theseneurons, high levels
of acetylated tubulin enhance the binding of motor protein kinesin-1 to
tubulin, which in turn promotes the transport of cargo and mitochondriaalong themicrotubules [63]. Pharmacological hyperacetylation of tubulin
(either with taxol or by means of Sirt2 inhibition) leads to mitochondrial
damage [64,65]. Interestingly, a recent study reports thatmutations in the
Roc Cor domain of LRRK2 make this protein more susceptible to bind to
non-acetylated microtubules and this causes axonal transport disruption
which can be restored by increasing tubulin acetylation [66]. The
Fig 6. Scheme illustrating the Bcl-xL-mediated antioxidant processes under GSK2578215A treatment in SH-SY5Y cells. Upon LRRK2 inhibition with GSK2578215A, a rise in tubulin acet-
ylation takes place resulting inmitochondrial fragmentation that leads to an overproduction of ROS. In addition, tubulin hyperacetylation disrupts autophagyﬂux, impeding a proper elim-
ination of damaged mitochondria. Bcl-xL exerts a protective effect by 3 mechanisms: a) lowering tubulin hyperacetylation and subsequent mitochondrial ﬁssion, b) avoiding GSH
depletion and thus preventing mitochondrial ROS-induced autophagic response and, c) restoring autophagy ﬂux.
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known.However, the observation that the presence of the ROS scavenger,
tempol, lowered the levels of acetylated tubulin in our cells, points to ROS
as the connection between Bcl-xL and tubulin acetylation. In keepingwith
this idea, recent evidence suggests that ROS activates AMPK, which in
turn, stimulates tubulin acetyltransferase protein, MEC-17. This ﬁnally
triggers tubulin acetylation [67].
In summary, data reported in this study identify Bcl-xL as a critical
regulator of the cell death and autophagic effects caused by the LRRK2 in-
hibitor GSK2578215A in SH-SY5Y cells.We demonstrate that Bcl-xL abro-
gates the GSK2578215A-activated dynamic mitochondrion-dependent
pathway process by inhibiting Bax and Drp-1 translocation. Moreover,
Bcl-xL modulated the GSK2578215A activated autophagy response by
preventing mitochondrial alterations through mechanisms involving
anti-oxidant-dependent inhibition of tubulin hyperacetylation. Fig. 6
summarizes the effects of LRRK2 inhibition in wild type cells and in
those overexpressing Bcl-xL.Conﬂict of interest
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